schizophrenia - Medxy AI

Elevated Serotonin Release in Schizophrenia: New Insights Into Negative Symptom Pathophysiology

By MedXY 12/17/2025

A PET imaging study reveals increased frontal serotonin release in schizophrenia, particularly in deficit type, tied to worse negative symptoms.

news Psychiatry

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

By MedXY 11/30/2025

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological challenges in developing treatments for cognitive impairment associated with schizophrenia.

Neurology news Psychiatry

Reduced Brain Iron Linked to Striatal Hyperdopaminergia in Schizophrenia: Insights from QSM MRI and PET Imaging

By MedXY 10/30/2025

This study reveals that lower brain iron levels in the substantia nigra-ventral tegmental area are associated with elevated striatal dopamine synthesis in schizophrenia, highlighting a potential new target for therapeutic intervention.

news Psychiatry Radiology

Unveiling the Iron-Dopamine Link in Schizophrenia: Insights from QSM MRI and PET Imaging

By MedXY 10/30/2025

This study reveals reduced brain iron in the substantia nigra-ventral tegmental area correlating with increased striatal dopamine synthesis in schizophrenia, suggesting novel neurobiological mechanisms and potential therapeutic targets.

news Psychiatry

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care

By MedXY 10/30/2025

An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.

news Psychiatry

Comparative Efficacy and Tolerability of Seven Antipsychotics in Acute Schizophrenia: Insights from a Large Multicenter Randomized Trial

By MedXY 10/29/2025

A multicenter randomized trial comparing seven antipsychotics in acute schizophrenia shows olanzapine and risperidone outperform several agents in efficacy but differ markedly in side effects, clarifying treatment choices.

Neurology news Psychiatry

Regional Specificity of Layer 3 Dendritic Spine Deficits in Schizophrenia: Implications for Cortical Circuit Dysfunction

By MedXY 10/27/2025

This study reveals region- and size-specific dendritic spine deficits in cortical layer 3 neurons of schizophrenia patients, highlighting differential synaptic disruptions across visual and prefrontal cortical areas underpinning cognitive deficits.

Diabetes & Endocrinology Psychiatry Specialties

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY 10/22/2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychiatric symptoms.

Internal Medicine Psychiatry Specialties

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study

By MedXY 10/18/2025

This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.

Clinical Updates news Psychiatry

Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence

By MedXY 09/21/2025

This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonstrating safety and modest efficacy.

Psychiatry Specialties

Clozapine and Infection Risk in Schizophrenia: Insights from a Hong Kong Population Study

By MedXY 08/22/2025

This study reveals an increased risk of infections among schizophrenia patients treated with clozapine compared to olanzapine, highlighting the need for vigilant infection monitoring and preventive care.

Clinical Updates news Psychiatry Specialties

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY 08/03/2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

AI Clinical Updates news Psychiatry Specialties

Comparative Analysis of Virtual Reality Therapies for Psychotic Symptoms: Auditory Hallucinations vs. Persecutory Delusions

By MedXY 08/02/2025

Two randomized controlled trials evaluated immersive VR therapies targeting auditory verbal hallucinations and persecutory delusions in schizophrenia and psychosis, revealing modest benefits for hallucinations but no superior effect for cognitive VR therapy in delusions.